Price$88.42-0.41 (-0.46%)
05:00 PM07:30 PM
News · 26 weeks27+50%
2026-04-192026-10-11
Mix1090d
- SEC Filings4(40%)
- Earnings2(20%)
- Insider2(20%)
- Analyst1(10%)
- Other1(10%)
Latest news
25 items- INSIDERDirector Kiani Joe E converted options into 698 shares (SEC Form 4)4 - IRADIMED CORP (0001325618) (Issuer)
- PRIRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities ConferenceORLANDO, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION ("Iradimed") (NASDAQ:IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 5th Annual ROTH Healthcare Opportunities Conference. Iradimed’s CFO, Jack Glenn, will host one-on-one meetings between company management and investors at the 5th Annual ROTH Healthcare Opportunities Conference at the Metropolitan Club in New York on September 29, 2026. About IRADIMED CORPORATION IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging ("MRI") compatible medical devices. We design, manufacture, market, an
- ANALYSTNeedham initiated coverage on iRadimedNeedham initiated coverage of iRadimed with a rating of Hold
- INSIDERDirector Allen Monty K sold $122,622 worth of shares (1,419 units at $86.41), decreasing direct ownership by 7% to 19,581 units (SEC Form 4)4 - IRADIMED CORP (0001325618) (Issuer)
- SECSEC Form 144 filed by iRadimed Corporation144 - IRADIMED CORP (0001325618) (Subject)
- SECAmendment: iRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Other Events8-K/A - IRADIMED CORP (0001325618) (Filer)
- SECSEC Form 10-Q filed by iRadimed Corporation10-Q - IRADIMED CORP (0001325618) (Filer)
- SECiRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IRADIMED CORP (0001325618) (Filer)
- PRIRADIMED CORPORATION Reports Second Quarter 2026 Financial ResultsAnnounces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $20.5 million for the second quarter of 2026, which increased by $0.1 million, or 0.5% compared to the same period in 2025.Reports GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46 for the second quarter of 2026.Declares a regular quarterly cash dividend of $0.20 per share of common stock for the second quarter of 2026, payable on August 28, 2026. ORLANDO, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ:IRMD) announced today its financial results for the three and six months ended June 30, 20
- PRIRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026ORLANDO, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2026 second quarter financial results before the market opens on Friday, July 31, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BIc3b3caa4c4d94098970951ede5eb5d2e Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-tim
- SECiRadimed Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - IRADIMED CORP (0001325618) (Filer)
- INSIDERCFO Glenn John converted options into 5,796 shares and covered exercise/tax liability with 2,319 shares, increasing direct ownership by 41% to 11,937 units (SEC Form 4)4 - IRADIMED CORP (0001325618) (Issuer)
- INSIDERDirector Scharen-Guivel Hilda Frederique sold $285,000 worth of shares (3,000 units at $95.00), decreasing direct ownership by 35% to 5,598 units (SEC Form 4)4 - IRADIMED CORP (0001325618) (Issuer)
- INSIDERCEO, President, Chairman Susi Roger E. sold $226,507 worth of shares (2,500 units at $90.60) as part of a pre-agreed trading plan (SEC Form 4)4 - IRADIMED CORP (0001325618) (Issuer)
- INSIDERCEO, President, Chairman Susi Roger E. sold $691,044 worth of shares (7,500 units at $92.14) as part of a pre-agreed trading plan (SEC Form 4)4 - IRADIMED CORP (0001325618) (Issuer)
- INSIDERCEO, President, Chairman Susi Roger E. sold $657,265 worth of shares (7,500 units at $87.64) as part of a pre-agreed trading plan (SEC Form 4)4 - IRADIMED CORP (0001325618) (Issuer)
- PRIRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceORLANDO, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), a leader in developing innovative MRI-compatible medical devices, today announced that Roger Susi, President and Chief Executive Officer, and Jack Glenn, Chief Financial Officer, will attend the Goldman Sachs 47th Annual Global Healthcare Conference, to be held June 8–10, 2026, at the Loews Miami Beach Hotel, Miami Beach, Florida. Investors interested in meeting with Iradimed management during the conference may contact their Goldman Sachs representative to schedule a one-on-one meeting. About IRADIMED CORPORATION IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging ("MRI"
- SECAmendment: SEC Form SCHEDULE 13G/A filed by iRadimed CorporationSCHEDULE 13G/A - IRADIMED CORP (0001325618) (Subject)
- INSIDERCEO, President, Chairman Susi Roger E. sold $631,341 worth of shares (7,500 units at $84.18) as part of a pre-agreed trading plan (SEC Form 4)4 - IRADIMED CORP (0001325618) (Issuer)
- INSIDERCEO, President, Chairman Susi Roger E. sold $642,862 worth of shares (7,500 units at $85.71) as part of a pre-agreed trading plan (SEC Form 4)4 - IRADIMED CORP (0001325618) (Issuer)
- SECSEC Form 10-Q filed by iRadimed Corporation10-Q - IRADIMED CORP (0001325618) (Filer)
- SECiRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IRADIMED CORP (0001325618) (Filer)
- PRIRADIMED CORPORATION Reports First Quarter 2026 Financial ResultsAnnounces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025.Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.Declares a regular quarterly cash dividend of $0.20 per share of common stock for the second quarter of 2026, payable on May 29, 2026. ORLANDO, Fla., May 01, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ:IRMD)
- SECSEC Form DEF 14A filed by iRadimed CorporationDEF 14A - IRADIMED CORP (0001325618) (Filer)
- INSIDERCEO, President, Chairman Susi Roger E. sold $657,709 worth of shares (7,500 units at $87.69) as part of a pre-agreed trading plan (SEC Form 4)4 - IRADIMED CORP (0001325618) (Issuer)
IRMD FAQ
8 questionsWhat does iRadimed Corporation do?
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute...Where does IRMD stock trade?
iRadimed Corporation (IRMD) is listed on NASDAQ.What sector and industry is IRMD in?
iRadimed Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did iRadimed Corporation go public?
iRadimed Corporation (IRMD) completed its IPO in 2014.Does IRMD pay a dividend?
IRMD's most recent ex-dividend date was 2026-08-14 with a cash dividend of $0.20 per share. No future ex-date is on file yet.What are analysts saying about IRMD?
iRadimed Corporation has had 2 recent analyst actions on file. The most recent action was from Needham: Hold on 2026-09-22.What companies are similar to IRMD?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare IRMD side-by-side with any of them on Quantisnow.How can I track IRMD on Quantisnow?
Quantisnow aggregates iRadimed Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IRMD to receive live email and push alerts on every new disclosure.